Injury Associated Articles & Analysis
23 news found
Europe-wide aid project for the protection of people with paraplegia Cologne, 28/05/2020 – COVID-19 can be particularly dangerous for people with severe spinal cord injuries. That is why FARCO-PHARMA supports the European Spinal Cord Injury Federation (ESCIF) and the Association of Paraplegics in Germany e.V. ...
I worked for more than 10 years in a foundation dedicated to the rehabilitation of people with spinal cord injury and other pathologies of neurological origin. What role does physical therapy play in the daily life of a person with spinal cord injury? ...
He is on the Board of Directors for the German Spinal Cord Injury Foundation and is Chair of the International Standards Committee at the American Spinal Injury Association (ASIA). ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive ...
(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 blocker, ...
Key findings from the studies showed that while CBD and KLS-13019 were both effective in preventing the development of pain associated with CIPN, KLS-13019 was also able to reverse CIPN-related pain – while CBD proved ineffective in doing so. ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive ...
Under the PCT Patent, Neuropathix novel therapeutic compounds have the potential to target diseases that include neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, ...
"There is something fundamental about this striking instance of molecular mimicry that we believe sets the stage for focussed experimental evaluation," said Venky Soundararajan, PhD, co-founder and chief scientific officer of nference. "Cardiac injury is a complication that is associated with severe COVID-19. Our unexpected molecular findings offer a potential ...
The therapeutic targets include CIPN, a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic ...
” The same article notes that good patient experience is “associated with lower medical malpractice risk,” as well as greater employee satisfaction, higher patient loyalty, and even better healthcare outcomes. ...
ByBioVigil
While our early studies in animals have shown evidence for an unprecedented reversal of pain associated with chemotherapy, our future studies will be used to ensure safe dosing and further details on the novel anti-neuroinflammatory mechanisms that help to understand how our new drug candidate works,” said Douglas Brenneman, PhD, Chief Pharmacologist of Neuropathix. ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive ...
The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive ...
Published in this month’s Experimental Physiology, the study, entitled, “Temporal changes in pulmonary gas exchange efficiency when breath-hold diving below residual volume,” demonstrated that breath-hold diving to depths associated with major lung compression, or “lung squeeze,” caused acute impairments in pulmonary gas exchange. Prior to this ...
Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols” The seventeen (17) foreign patents claim priority to Kannalife’s original 2014 U.S. filing through international application PCT/US2015/010827, which was published as ...
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic ...
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic ...
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic ...
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic ...